Shares of Dr Reddy’s Labs yet again plunged sharply; after the USFDA warned that if the company fails to take corrective actions at three of its manufacturing facilities it may lead to imposition of an import ban on these units. Commenting on the same, Amar Ambani, Head of Research, IIFL, said, “Details of warning letter released by FDA compounds the regulatory woes for Dr Reddy’s as the nature of violations suggests stretched resolution time lines along with associated costs; we retain positive bias for now though escalation into an import alert remains a key risk to our view.”